Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Oct 01, 2018 5:43pm
175 Views
Post# 28725047

RE:RE:RE:WHY/When

RE:RE:RE:WHY/When
Jefferam1 wrote: The incentive to trade on NASDAQ is US exposure (shareholder value) we already have Canadian exposure on TSXV so no real reason to go to TSX. At least not yet anyway.
Sure they have a slim bit of US exposure with OTC but that doesn't really count.

TSX could come in future, no urgent need now.


My question is would a Nasdaq listing impact the value ATE could negotiate for the marketing rights in the US/EU?

That's the point I'm waiting for to make any significant decisions about my holding. That's what's going to fix the value of this drug in my mind (with or without Nasdaq).

I dont think it does make any difference. I'd rather get to that point without any further dilution if we have the cash to do that. Maybe people are looking for more trading opportunities between now and any deal, I can see it might (or might not) help them. I'm happy to patiently wait for the clinical and business milestones outlined by the company. I dont need Nasdaq at this late stage in the process, I can wait a year for real big concrete value moments. (hopefully the pre-existing clinical milestones are going to be enough to make us happy over the coming months)

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities